On September 24, 2015, the U.S. Court of Appeals for the Federal Circuit affirmed summary judgment of non-obviousness of 18 claims from four patents protecting Shire’s blockbuster drug Vyvanse® (lisdexamfetamine dimesylate).
Ready-to-use CARDENE® I.V. Premixed Injection is indicated for the short-term treatment of hypertension and is the only available FDA-approved premixed formulation of nicardipine hydrochloride. Chiesi USA, Inc. owns four patents listed in the FDA’s Orange Book as covering CARDENE® I.V. Premixed Injection—U.S. Patent Nos. 7,612,102, 7,659,291, 8,455,524, and 7,659,290.